/Bio-Techne%20Corp%20logo%20and%20data-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Bio-Techne Corporation (TECH), headquartered in Minneapolis, Minnesota, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. Valued at $8.4 billion by market cap, the company specializes in proteins, cytokines, growth factors, immunoassays and small molecules.
Shares of this leading life sciences reagents and instruments company have considerably underperformed the broader market over the past year. TECH has declined 28.5% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 16.1%. In 2025, TECH stock is down 26%, compared to the SPX’s 9.7% rise on a YTD basis.